Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MDMA
Biotech
Jupiter enters psychedelics space with $100M deal for MDMA drug
Jupiter will pay $3.3 million upfront to Canada's PharmAla Biotech for U.S. rights to an MDMA drug to treat neuropsychiatric disorders.
Marissa Russo
Jul 21, 2026 10:00am
AtaiBeckley's MDMA drug improves anxiety in ph. 2 trial
Feb 26, 2026 1:32pm
Transcend links MDMA analog to PTSD improvements in phase 2
Mar 31, 2025 8:00am
Lykos still plotting path to approval for rejected MDMA therapy
Jan 17, 2025 9:00am
Lykos accepts FDA view that MDMA med needs new trial for approval
Oct 21, 2024 8:31am
After FDA rejection and layoffs, Lykos' CEO is leaving
Sep 5, 2024 1:39pm
